Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantum Simulation of Pseudo-Hermitian-<i>φ</i>-Symmetric Two-Level Systems.

Entropy (Basel, Switzerland)·2022
Same author

Unexpected toroidal micelles formed from St/MMA gradient copolymers.

Soft matter·2022
Same author

Characterization of <i>Pseudomonas aeruginosa</i> Bacteriophage L5 Which Requires Type IV Pili for Infection.

Frontiers in microbiology·2022
Same author

Constructing high-performance TADF polymers from non-TADF monomers: a computational investigation.

Physical chemistry chemical physics : PCCP·2022
Same author

Research on the Mechanical Properties and Stretch Forming Simulation of Triaxial Geogrid with Different Pre-Punched Hole Diameters.

Polymers·2022
Same author

Spatial distribution of soil nutrients and evaluation of cultivated land in Xuwen county.

PeerJ·2022
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Hannah Le1,2, Roger Raymond2, Neil Vasdev1,2

  • 1University of Toronto, Toronto, ON, Canada.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) brains show decreased synaptic vesicle glycoprotein 2A (SV2A) and purinergic receptor P2Y12R, alongside increased tau. These changes correlate, offering insights into AD progression and potential imaging biomarkers.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Alzheimer's disease (AD) is characterized by complex neuropathological changes.
  • Synaptic vesicle glycoprotein 2A (SV2A), purinergic receptor P2Y12R, and hyperphosphorylated tau are key targets in AD research.
  • Understanding the interplay between SV2A, P2Y12R, and tau is crucial for advancing AD diagnostics and therapeutics.

Purpose of the Study:

  • To investigate the expression and distribution of SV2A, P2Y12R, and tau in postmortem brain tissues from AD patients and cognitively normal controls (CN).
  • To evaluate the correlation between the binding of radiotracers for SV2A ([3H]UCB-J), P2Y12R ([3H]PSB-0413), and tau ([18F]MK-6240) in AD brains.

Main Methods:

  • In vitro autoradiography (ARG) using specific radiotracers ([3H]PSB-0413, [3H]UCB-J, [18F]MK-6240) on postmortem hippocampal and entorhinal cortex tissues.
  • Quantification of radiotracer binding using digital ARG and determination of non-specific binding.
  • Binding correlation analysis was performed on regional data from AD patients.

Main Results:

  • Decreased binding of [3H]PSB-0413 (P2Y12R) was observed in the subiculum (SUB) and entorhinal cortex (EC) of AD patients compared to CN.
  • [3H]UCB-J (SV2A) binding was significantly reduced in the dentate gyrus (DG), CA1, and EC of AD patients.
  • [18F]MK-6240 binding (tau) was increased in the CA1 and SUB regions of AD patients, consistent with tau aggregate localization.
  • Significant positive correlations were found between the regional binding of [3H]UCB-J, [3H]PSB-0413, and [18F]MK-6240 in AD brains.

Conclusions:

  • SV2A levels decrease, tau accumulations increase, and P2Y12R expression is reduced in AD brains.
  • The findings align with in vivo human PET imaging studies for SV2A and tau.
  • The observed correlations suggest a potential link between synaptic density, microglial activation, and tau pathology in AD progression.